Trials / Unknown
UnknownNCT02778854
Liquid Biopsy for Detection of Driver Mutation in NSCLC
Liquid Biopsy for Detection of Driver Mutation in Diagnostic and Prognostic of NSCLC
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the diagnostic and prognostic efficacy of liquid biopsy in different specimens and in different methods compared with tissue detection .
Detailed description
Collect plasma and other specimens from patients who are newly diagnosed with NSCLC or with drug-resistant and plan to receive gene detection to complete the diagnostic test for liquid biopsy .Participants who come from diagnostic test and plan to receive tyrosine kinase inhibitors (TKI) therapy will be collected plasma and other specimens every month during the regiments and monitor the changes of driver motion to predict the prognosis of targeted therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | detection of driver mutation | participants are received gene detection via the liquid biopsy |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-12-01
- Completion
- 2020-11-01
- First posted
- 2016-05-20
- Last updated
- 2018-03-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02778854. Inclusion in this directory is not an endorsement.